63837-12-7

Basic information

• Product Name: 5-AMINOBENZOOXAZOLE
• Synonyms: 5-AMINOBENZOOXAZOLE ;Benzooxazol-5-ylamine;5-Aminobenzoxazol;benzo[d]oxazol-5-aMine;1,3-Benzoxazol-5-amine, 5-Aminobenzo[d]oxazole;1,3-Benzoxazol-5-aMine, >95%
• CAS NO: 63837-12-7
• Molecular Formula: C₇H₆N₂O
• Molecular Weight: 134.13534
• Product Categories: Amines;Oxazoles, Isoxazoles & Benzoxazoles;Oxazoles, Isoxazoles & Benzoxazoles
• Mol File: 63837-12-7.mol

Chemical Properties

• Melting Point: 64-66°C
• Boiling Point: 282.3°C at 760 mmHg
• Flash Point: 124.5°C
• Appearance: /
• Density: 1.317g/cm³
• Vapor Pressure: 0.00339mmHg at 25°C
• Refractive Index: 1.685
• PKA: 6.97±0.10(Predicted)
• CAS DataBase Reference: 5-AMINOBENZOOXAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-AMINOBENZOOXAZOLE(63837-12-7)
• EPA Substance Registry System: 5-AMINOBENZOOXAZOLE(63837-12-7)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 63837-12-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-Aminobenzooxazole is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of biologically active compounds. Its structural properties allow it to interact effectively with biological systems, enhancing the therapeutic potential of the resulting medications.
Used in Organic Synthesis:
In the realm of organic synthesis, 5-Aminobenzooxazole serves as a valuable building block, facilitating the creation of a wide array of chemical compounds. Its reactivity and structural features make it an essential component in the production of various organic materials.
Used in Medicine and Biochemistry:
5-Aminobenzooxazole is utilized in medicine and biochemistry due to its potential to engage with biological systems. Its unique properties position it as a promising candidate for the advancement of medical research and the development of new biochemical applications.

InChI:InChI=1/C7H6N2O/c8-5-1-2-7-6(3-5)9-4-10-7/h1-4H,8H2

Upstream product

• 99-57-0 2-hydroxy-5-nitroaniline 
• 70886-33-8 5-nitro-benzooxazole 

Downstream Products

• 1620292-42-3 phenyl benzo[d]oxazol-5-ylcarbamate 

Relevant articles and documents

ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE "RIG-I' PATHWAY AND METHODS OF USE THEREOF

The present invention is directed to compounds of Formula (I), which are activators of the RIG-I pathway.

ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE "RIG-I" PATHWAY AND METHODS OF USE THEREOF

The present invention is directed to compounds of Formula (I), which are activators of the RIG-I pathway.

SUBSTITUTED SPIROCYDIC INHIBITORS OF AUTOTAXIN

The present invention relates to compounds according to Formula 1 and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancer, lymphocyte homing, chronic inflammation, neuropathic pain, fibrotic diseases, thrombosis, and cholestatic pruritus, mediated at least in part by ATX.

Polymethylhydrosiloxane derived palladium nanoparticles for chemo- and regioselective hydrogenation of aliphatic and aromatic nitro compounds in water

Chemo- and regioselective hydrogenation of a wide range of aliphatic, unsaturated, aromatic and heteroaromatic nitro compounds into their corresponding amines has been achieved with highly efficient polysiloxane-stabilised "Pd" nanoparticles on NAP-magnesium oxide supports using an environmentally friendly hydrogenating agent, polymethylhydrosiloxane [PMHS] in water. Highly stable and active Pd nanoparticles were prepared by the reduction of NAP-Mg-PdCl4 with PMHS, which serves as a reducing agent as well as a capping agent. The well-dispersed palladium nanoparticles on NAP-MgO catalysts also exhibit excellent regioselectivity in the hydrogenation of dinitrobenzenes to the corresponding nitroanilines. The catalyst has high durability against sintering during the hydrogenation reaction and can be reused with no loss in its activity. This journal is the Partner Organisations 2014.

Vanilloid receptor ligands and their use in treatments

Compounds having the general structure and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritis, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders.

Gould-Jacobs reaction of 5- and 6-amino-2-substituted benzoxazoles. I. Reaction with diethyl ethoxymethylenemalonate

Reaction of 2-substituted 5- and 6-aminobenzoxazoles 1 and 2 with diethyl ethoxymethylenemalonate afforded the corresponding diethyl 3-N-(5- and 6-benzoxazolyl)aminomethylenemalonates 3 and 4. Under conditions of the Gould-Jacobs reaction, the compounds 3

Gould-jacobs reaction of 5- and 6-amino-2-substituted benzoxazoles. II. Reaction with 3-ethoxymethylene-2,4-pentanedione and ethyl 2-ethoxymethylene-3-oxobutanoate

Nucleophilic reaction of 5-amino- and 6-amino-2-substituted benzoxazoles 1 and 2 with 3-ethoxymethylene-2,4-pentanedione (3) gave compounds 5 and 6. Compounds 1 and 2 reacted with ethyl ethoxymethylene-3-oxobutanoate (4) under formation of compounds 7 and